Drug Regulatory Authority of Pakistan (DRAP) has granted Emergency Use Authorization (EUA) to the COVID-19 vaccine developed by Pfizer.
According to details, Pfizer’s COVID-19 vaccine will be administered to the immuno-compromised population on a priority basis because European and Chinese vaccines are not suitable for people with underlying health conditions.
Pfizer’s COVID-19 vaccine is the sixth vaccine that has been approved by DRAP for use across the country. DRAP has previously approved three Chinese vaccines developed by Sinopharm, Cansino, and Sinovac. Russia’s Sputnik V and AstraZeneca’s AZD1222 are the other two vaccines approved by DRAP.
Last week, Pakistan received the first shipment comprising 106,000 doses of Pfizer’s mRNA vaccine through COVAX, a worldwide initiative aimed at equitable access to COVID-19 vaccines led by GAVI.
The Pfizer vaccine is stored at -70 °C. The Pfizer vaccine acquired through COVAX has been stored in 23 Ultra Cold Chain (UCC) refrigerators across the country.
The two-dose Pfizer’s vaccine is 95% effective at preventing COVID-19 infection in those with no prior infections.
Besides, Pakistan is also buying 1 million doses of Pfizer’s COVID-19 vaccine directly from the New York-based pharmaceutical company.
The first batch of the directly acquired Pfizer vaccine will reach the country in July or August.